Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics
Gilead Sciences, Inc. (Nasdaq: GILD) announced today the promotion of Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs, including cell therapy research and development. Dr. Riva will become a member of Gilead’s senior leadership team.
Dr. Riva joined Gilead in January 2017 as Senior Vice President, Hematology and Oncology Therapeutic Area Head. He has been instrumental in expanding Gilead’s oncology program with the recent acquisition of Kite Pharma, establishing the company as a leader in the field of cellular therapy. He has also guided the strategy and development of Gilead’s broader oncology pipeline during his tenure.
Prior to joining Gilead, Dr. Riva served as Head, Global Oncology Development at Novartis, where he oversaw the development and worldwide regulatory approval of multiple compounds in a variety of tumor types. He received his bachelor’s degree in Medicine and a Certificate Board in Oncology/Hematology from the School of Medicine of Milan. Earlier in his career, he worked as a physician, treating patients with hematological malignancies at the University Hospital of Milan.
“Alessandro’s vision and insight have helped Gilead broaden and deepen our oncology pipeline through the acquisition of Kite Pharma, and his exceptional leadership has guided the company’s broader hematology/oncology strategy,” said John McHutchison, MD, Executive Vice President, Clinical Research. “In his new role, I am confident that Gilead’s hematology and oncology programs will continue to expand, as we seek to advance new therapies with the potential to transform the treatment of patients with cancer.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000
Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Amy Flood, 650-522-5643
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
LIVANOVA-PLC20.11.2017 09:45 | pressemeddelelse
LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million
CHUGAI-PHARMACEUTICAL20.11.2017 09:31 | pressemeddelelse
Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study
CA-SYNTERACT20.11.2017 09:02 | pressemeddelelse
Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam
FIORANO-SOFTWARE20.11.2017 09:02 | pressemeddelelse
Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance
JAPAN-CONTENT-SHOWCASE20.11.2017 04:02 | pressemeddelelse
Record Attendance at Japan Content Showcase 2017!
SHELL/BIO-BEAN20.11.2017 01:03 | pressemeddelelse
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum